Ahead of the 2025 J.P. Morgan Healthcare Conference scheduled to take place in a few days, Oppenheimer named five potential buyout candidates in biotech on Friday, naming obesity drug developer Viking ...

Oppenheimer laid out five “aspirational” potential takeover targets in biotech heading into the annual JPMorgan Health Care Conference. “We ...

Regulators approved the first bespoke cell therapies for solid tumors this year, while drugmakers expanded and improved upon ...

Arcellx shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.

Arcellx shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.

Arcellx, Inc. (NASDAQ:ACLX), a U.S. biopharmaceutical company valued at $4.51 billion, has been making waves in the biotechnology sector with its innovative approach to cell therapy for multiple ...

Arcellx, Inc. (NASDAQ:ACLX – Get Free Report)’s share price rose 5.1% on Wednesday after UBS Group raised their price target on the stock from $106.00 to $114.00.UBS Group currently has a buy ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...